Therapy of heart failure with β-blockers;Therapie der Herzinsuffizienz mit β-Blockern?

Zeitschrift fur Kardiologie

Volumn 86, Issue 1, 1997, Pages 1-8

  Osterziel, K J ^a   Dietz, R ^a  

^a Franz Volhard Klinik   (Germany)

Author keywords

exercise capacity; heart failure; prognosis; blocker

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; LABETALOL; METOPROLOL; NEBIVOLOL;

HEART FAILURE; HEMODYNAMICS; HUMAN; REVIEW;

EID: 0030901925     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00007336     Document Type: Review

References (63)

1. Anderson JL, Lutz JR, Gilbert EM, Sorensen SG, Yanowitz FG, Menlove RL, Bartholomew M (1985) A randomized trial of low-dose-beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 55:471-475
2. Andersson B, Hamm C, Persson S, Wilkstrom G, Sinagra G, Hjalmarson A, Waagstein F (1994) Improved exercise hemodynamic status in dilated cardiomyopathy after beta-adrenergic blockade treatment. J Am Coll Cardiol 23:1397-1404
3. Australia-New Zealand Heart Failure Research Collaborative Group (1995) Effects of Carvedilol, a vasodilator-β blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 92: 212-218
4. Bristow MR, Anderson FL, Port D, Skerl L, Hershberger RE, Larrabee P, O'Connell JB, Renlund DG, Volkman K, Murray J, Feldman AM (1991) Differences in β-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation 84:1024-1039
5. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger R, Kubo SH, Narahara KA, Ingersoll H (1995) Multicenter oral carvedilol heart failure assessment (MOCHA): a six month dose-response evaluation in class II-IV patients. Circulation 92:1-142 (abstract)
6. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K Billingham ME, Harrison DC, Stinson EB (1982) Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N Engl J Med 307: 205-211
7. 1-receptor down-regulation in heart failure. Circ Res 59: 297-309
8. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P, Deitchman D, Anderson JL (1994) Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 89:1632-1642
9. Brodde OE (1990) Physiology and pharmacology of cardiovascular catecholamine receptors: implications for treatment of chronic heart failure. Am Heart J 120: 1565-1572
10. Cibis Investigators and Committees (1994) A randomized trial of β-blockade in heart failure (CIBIS). Circulation 90:1765-1773
11. Conn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman B, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes V, Carson P, Cintron G, Shabetai R, Haakenson C (1991) A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325:303-310
12. Colucci WS, Packer M, Bristow MR, Conn JN, Fowler MB, Gilbert EM, Krueger SK, Adams KF, Hershberger R, Uretsky BF (1995) Carvedilol inhibits clinical progression in patients with mild heart failure. Circulation 92:1-395 (abstract)
13. Davies RF, Beanlands DS, Nadeau C, Phaneuf D, Morris A, Arnold JM, Parker JO, Baigrie R, Latour P, Klinke WP, Bernstein V, Leblanc M-H, Mizgala H, Stevens A, Boisvert G (1991) Enalapril versus digoxin in patients with congestive heart failure: a multicenter study. J Am Coll Cardiol 18: 1602-1609
14. Digitalis Investigator Group (1996) The effect of digitalis on mortality and hospitalizations in patients with heart failure. JACC 27 (suppl A)
15. Doughty RN, MacMahon S, Sharpe N (1994) Beta-blockers in heart failure: promising or proved? JACC 23:814-821
16. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux LG, Malloy CR (1994) Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 24: 1310-1320
17. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM (1985) Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 72:536-546
18. Feldmann AM (1993) Modulation of adrenergic receptors and G-transduction proteins in failing human ventricular myocardium. Circulation 87 (suppl IV):27-34
19. Fisher ML, Gottlieb SS, Plottnick GD, Greenberg NL, Patten RD, Bennett SK, Hamilton BP (1994) Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. JACC 23:943-950
20. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR (1986) Assessment of the β-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation 74: 1290-1302
21. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A (1993) Plasma norepinephrine plasma renin activity, and congestive heart failure. Circulation 87 suppl VI-40-VI-48
22. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, Bartholomew M, Mealey PC, Larrabee P, Bristow MR (1990) Long-term b-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 88: 223-229
23. Gilbert EM, Olsen SL, Renlund DG, Bristow MR (1993) Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol 71:23C-29C
24. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ (1995) Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. JACC 25: 1154-1161
25. Hasenfuss G, Reinecke H, Studer R, Meyer M, Pieske B, Holtz J, Holubarsch C, Posival H, Just H, Drexler H (1994) Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium. Cire Res 75:434-442
26. Heesch CM, Marcoux L, Hatfield B, Eichhorn EJ (1995) Hemodynamic and energetic comparison of bucindolol and metroprolol for the treatment of congestive heart failure. Am J Cardiol 75:360-364
27. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB (1989) Increased b-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 79:483-490
28. Ikram H, Fitzpatrick D (1981) Double-blind trial of congestive oral beta blockade in congestive cardiomyopathy. Lancet 490-493
29. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin HR, Neuberg GW, Delong G, Packer M (1995) Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 92: 1499-1506
30. Kukin ML, Kalman F, Mannino M, Freudenberger R, Buchholz C, Ocampo O (1996) Combined alpha-beta-blockade (doxazosin plus metoprolol) compared with beta blockade alone in chronic congestive heart failure. Am J Cardiol 77: 486-491
31. Leung W-H, Lau C-P, Wong C-K, Cheng C-H, Tai Y-T, Lim S-P (1990) Improvement in exercise performance and hemodynamics bei labetalol in patients with idiopathic dilated cardiomyopathy. Am Heart J 119: 884-890
32. Luu M, Stevenson WG, Stevenson LW, Baron K, Walden J (1989) Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 80: 1675-1680
33. 1-adrenoceptor with positive chronotropic effect. Circulation 89:2760-2767
34. Metra M, Nardi M, Giubbini R, Cas LD (1994) Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. JACC 24:1678-1687
35. Neumann J, Scholz, H, Döring V, Schmitz, W, von Meyernick L, Kalmar P (1988) Increase in myocardial Gi-proteins in heart failure. Lancet 936-937
36. Olsen SL, Gilbert EM, Tenlund DG, Taylor DO, Yanowitz FD, Bristow MR (1995) Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. JACC 25:1225-1231
37. Osterziel KJ, Dietz R, Manthey J, Schmid W, Kübler W (1990) Haemodynamic changes caused by alteration of autonomie activity in patients with heart failure. Br Heart J 63:221-224
38. Packer M (1993) The development of positive inotropic agents for chronic heart failure: how have we gone astray? J Am Coll Cardiol 22:119A-126A
39. Packer M, Bristow MR, Conn J, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, and For the U.S. Carvedilol Heart Failure Study Group (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1355
40. Packer M, Bristow MR, Cohn JN: Colucci WS, Fowler MB, Gilbert EM (1995) Effect of carvedilol on the survival of patients with chronic heart failure. Circulation 92: 1-142 (abstract)
41. Packer M, Carver JR, Rodehefter RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML: Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL (1991) Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325 No 21: 1468-1475
42. Packer M, Colucci WS, Sackner-Bernstein J, Liang C, Goldschef DA, Freeman I, Kukin M, Kinhal V, Udelson JE, Klapholz M (1995) Prospective randomized evaluation of carvedilol on symptoms and exercise tolerance in chronic heart failure: results of the precise trial. Circulation 92: I-143 (abstract)
43. Packer M, Georghiade M, Young JB, Costantini PJ, Adams K, Cody RJ, Smith LK, Van Voorhees L, Gourley LA, Jolly K, and For the Radiance Study (1993) Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 329:1-7
44. Panfilov V, Wahlqvist I, Olsson G (1995) Use of beta-adrenoceptor blockers in patients with congestive heart failure. Cardiovasc Drugs Ther 9:273-287
45. Paolisso G, Gambardella A, Marrazzo G, Verza M, Teasuro P, D'Onofrio F (1992) Metabolic and cardiovascular benefits deriving from β-adrenergic blockade in chronic congestive heart failure. Am Heart J 123:103-110
46. Pfeffer MA, Stevenson LW (1996) β-adrenergic blockers and survival in heart failure. N Engl J Med 334:1396-1397
47. Pollock SG, Lystash J, Tedesco C, Craddick G, Smucker ML (1990) Usefulness of bucindolol in congestive heart failure. Am J Cardiol 66:603-607
48. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I (1980) Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J 44:117-133
49. Swedberg K, Waagstein F, Hjalmarson A, Wallentin I (1979) Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1:1374-1376
50. The Captopril Multicenter Research Group (1988) Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. J.A.M.A. 259: 539-544
51. The Consensus Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 316:1429-1435
52. The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection tractions and congestive heart failure. N Engl J Med 325: 293-302
53. The Xamoterol in Severe Heart Failure Study Group (1990) Xamoterol in severe heart failure. Lancet 336:1-6
54. 1-adrenergic receptors in the failing human heart. Circulation 87:454-463
55. Uretsky BF, Jessup M, Konstam MA, Dec W, Laier CV, Benotti J, Murali S, Herrmann HC, Sandberg JA, and for the Enoximone Multicenter Trial Group (1990) Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Circulation 82: 774-780
56. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC Jolly MK (1993) Randomized study assessing the effect of digoxon withdrawal in patients with mild to moderate chronic congestive heart failure: results of the proved trial. JACC 22/4: 955-962
57. Waagstein F, Bristow M, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A, and for the Metoprolol in Dilated Cardiomyopathy (MDC) Study Group (1993) Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342:1441-1446
58. Waagstein F, Caidahl K, Wallentin I, Bergh C-H, Hjalmarson A (1989) Long-term β-blockade in dilated cardiomyopathy. Circulation 80:551-563
59. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I (1975) Effect of chronic beta-adrenergic blockade in congestive cardiomyopathy. Br Heart J 37:1022-1026
60. Waagstein F, Sweedberg K, Hjalmarson A (1996) Improvement after metoprolol in idiopathic dilated cardiomyopathy is predicted by baseline systolic blood pressure and change in heart rate. JACC 27:170A
61. Wisenbaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middlemost S, Röthlisberger C, Skudicky D, Sareli P (1993) Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. JACC 21: 1094-1100
62. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, Menlove R, Bristow MR (1991) Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 84: 2426-2441
63. Yates JC, Beamish RE, Dhalla NS (1981) Ventricular dysfunction and necrosis produced by adrenochrome metabolite of epinephrine: relation to pathogenesis of catecholamine cardiomyopathy. Am Heart J 102:210-221